Women's health company Hologic Inc (Nasdaq:HOLX) on Thursday announced US FDA 510(k) clearance and European CE marking for its Panther Fusion Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays.
The assays are designed to rapidly detect common bacterial pathogens causing infectious gastroenteritis, including Salmonella, Campylobacter, Shigella, E. coli, Vibrio, Yersinia, and Plesiomonas.
The tests can be run individually or in combination, allowing labs to tailor diagnostics to patient needs while reducing testing time and streamlining workflows.
Hologic's assays operate on the Panther Fusion System, an add-on to the company's fully automated Panther System, which supports a broad menu of molecular diagnostics. The platform enables faster diagnosis and informed clinical management, and supports antimicrobial stewardship by guiding targeted antibiotic use.
These approvals position Hologic to expand its molecular diagnostic offerings for gastrointestinal infections globally.
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy
Centivax raises USD45m to commercialise universal flu vaccine
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval